Use: Labeled indications
- Hyperprolactinemia-associated dysfunction including amenorrhea with or without galactorrhea, infertility, or hypogonadism in adults
- Prolactin-secreting adenomas in adults and pediatric patients 11 years of age and older
- .
Full indications and usage US FDA label
1 INDICATIONS & USAGE Bromocriptine mesylate is an ergot derivative indicated for the treatment of: Hyperprolactinemia-associated dysfunction including amenorrhea with or without galactorrhea, infertility, or hypogonadism in adults (1.1) Prolactin-secreting adenomas in adults and pediatric patients 11 years of age and older (1.2). Acromegaly in adults (1.3).
Signs and symptoms of idiopathic Parkinson’s disease or postencephalitic parkinsonism in adults (1.4). Limitations of Use Avoid use of bromocriptine mesylate for the inhibition or suppression of postpartum physiologic lactation because of the risk of serious adverse reactions (1.1, 5.4) 1.1 Hyperprolactinemia-Associated Dysfunction Bromocriptine mesylate is indicated for the treatment of hyperprolactinemia-associated dysfunction including amenorrhea with or without galactorrhea, infertility or hypogonadism in adults.
Limitations of Use Avoid use of bromocriptine mesylate for the inhibition or suppression of postpartum physiologic lactation because of the risk of serious adverse reactions [see Warnings and Precautions (5.4)]. 1.2 Prolactin-Secreting Adenomas Bromocriptine mesylate is indicated for the treatment of prolactin-secreting adenomas in adults and pediatric patients 11 years of age and older. 1.3 Acromegaly Bromocriptine mesylate is indicated for the treatment of acromegaly in adults. 1.4 Idiopathic Parkinson’s Disease or Postencephalitic Parkinsonism Bromocriptine mesylate is indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease or postencephalitic parkinsonism in adults.
Contraindications
4 CONTRAINDICATIONS Bromocriptine mesylate is contraindicated in patients with: History of cardiac valvular disorders or a history of pericardial fibrosis [see Warnings and Precautions (5.1)]. History of pleural, pulmonary, or retroperitoneal fibrotic disorders [see Warnings and Precautions (5.2)]. Uncontrolled hypertension [see Warnings and Precautions (5.3)].
Hypersensitivity to bromocriptine or to any of the excipients of bromocriptine mesylate tablets or capsules or sensitivity to other ergot alkaloids. Bromocriptine mesylate is contraindicated in patients with: History of cardiac valvular disorders or a history of pericardial fibrosis (4, 5.1). History of pleural, pulmonary, or retroperitoneal fibrotic disorders (4, 5.2) Uncontrolled hypertension (4, 5.3) Hypersensitivity to bromocriptine or to any of the excipients of bromocriptine mesylate tablets or capsules or sensitivity to other ergot alkaloids (4).
US FDA labelDosing: Adult
- Before initiating bromocriptine mesylate, evaluate for valvular heart disease, including with an echocardiogram. If valvular disease is detected, do not administer bromocriptine mesylate (2.1). Take bromocriptine mesylate orally with food (2.2)
- Recommended dosage for hyperprolactinemia-associated dysfunction is 1.25 mg (one-half of a tablet) to 2.5 mg once daily. Increase the dosage up to 2.5 mg once daily every two to seven days within a recommended dosage of 2.5 mg to 15 mg once daily (2.3)
- Recommended dosage for prolactin-secreting adenomas is 1.25 mg to 2.5 mg once daily. Increase the dosage within a recommended dosage of 2.5 mg to 10 mg once daily (2.4)
- Recommended dosage for acromegaly is 1.25 to 2.5 mg once at bedtime for 3 days. Increase the dosage 1.25 mg to 2.5 mg once daily every 3 to 7 days up to the maximum recommended dosage is 100 mg/daily (2.5). Recommended starting dosage for idiopathic or postencephalitic Parkinson’s disease is 1.25 mg twice daily. Increase the dosage by 1.25 mg twice daily every 14 to 28 days up to the maximum recommended daily dosage of 100 mg/day (2.6)
- For dosage modifications for concomitant use of bromocriptine mesylate with moderate CYP3A4 inhibitors, see Full Prescribing Information (2.7, 7)
2.1 Recommended Evaluation
2.1 Recommended Evaluation Before Initiating Bromocriptine Mesylate Before initiating bromocriptine mesylate evaluate for valvular heart disease, including with an echocardiogram. If valvular disease is detected, do not administer bromocriptine mesylate [see Contraindications (4) and Warnings and Precautions (5.1)].
2.2 Important Administration Instructions
2.2 Important Administration Instructions Take bromocriptine mesylate orally with food because a high percentage of patients vomited after they received bromocriptine mesylate under fasting conditions.
2.3 Recommended Dosage for Hyperprolactinemia-Associated Dysfunction
2.3 Recommended Dosage for Hyperprolactinemia-Associated Dysfunction The recommended starting dosage of bromocriptine mesylate in adults with hyperprolactinemia-associated dysfunction is 1.25 mg (one-half of a tablet) to 2.5 mg once daily. Increase the bromocriptine mesylate dosage up to 2.5 mg once daily every two to seven days as tolerated until an optimal therapeutic response is achieved within a recommended dosage of 2.5 mg to 15 mg once daily.
2.4 Recommended Dosage for Prolactin-Secreting Adenomas
2.4 Recommended Dosage for Prolactin-Secreting Adenomas The recommended starting dosage of bromocriptine mesylate in adult and pediatric patients 11 years of age and older with prolactin-secreting adenomas is 1.25 mg (one-half of a tablet) to 2.5 mg once daily. Increase the bromocriptine mesylate dosage as tolerated until an optimal therapeutic response is achieved within a recommended dosage of 2.5 mg to 10 mg once daily.
In cases where adenectomy is elected for prolactin-secreting adenomas, a course of bromocriptine mesylate therapy may be used to reduce the tumor mass prior to surgery.
2.5 Recommended Dosage for Acromegaly
2.5 Recommended Dosage for Acromegaly The recommended starting dosage of bromocriptine mesylate in adults for acromegaly is 1.25 mg (one-half of a tablet) to 2.5 mg once at bedtime for 3 days. Increase the dosage 1.25 mg to 2.5 mg once daily every 3 to 7 days, as tolerated, until an optimal therapeutic response is achieved.
Reevaluate patients monthly and modify the dosage based on growth hormone levels and clinical response. For adults with acromegaly, the usual optimal therapeutic dosage range varies from 20-30 mg once at bedtime in most patients, and the maximum recommended dosage is 100 mg/daily. After a brief trial with bromocriptine mesylate therapy in adults with acromegaly, if there is no significant reduction in growth hormone levels and no changes in the clinical features of acromegaly consider increasing the dosage or discontinuing bromocriptine mesylate.
For patients with acromegaly treated with pituitary irradiation, withdraw bromocriptine mesylate (e.g., for four to eight weeks) on a yearly basis to assess the clinical effects of radiation on the disease process as well as the effects of bromocriptine mesylate therapy. Consider restarting bromocriptine mesylate if signs or symptoms of acromegaly or increases in growth hormone occur.
2.6 Recommended Dosage for Idiopathic Parkinson’s Disease or Postencephalitic
2.6 Recommended Dosage for Idiopathic Parkinson’s Disease or Postencephalitic Parkinson Parkinsonism The recommended starting dosage of bromocriptine mesylate in adults with idiopathic Parkinson’s disease or postencephalitic parkinsonism is 1.25 mg (one-half of a tablet) twice daily. Increase the dosage by 1.25 mg (one half of a tablet) twice daily every 14 to 28 days based on therapeutic response and tolerability, up to the maximum recommended daily dosage of 100 mg/day.
For patients receiving concomitant levodopa, maintain the levodopa dosage during bromocriptine mesylate dosage escalation. If the levodopa dosage is decreased, increase the bromocriptine mesylate dosage in increments of 1.25 mg twice daily.
2.7 Dosage Modification for Strong and Moderate CYP3A4 Inhibitors
2.7 Dosage Modification for Strong and Moderate CYP3A4 Inhibitors Avoid concomitant use of bromocriptine mesylate with strong CYP3A4 inhibitors. Dosage modifications of bromocriptine mesylate for concomitant use with moderate CYP3A4 inhibitors are provided in Table 1 [see Drug Interactions (7)]. Table 1. Dosage Modifications of Bromocriptine Mesylate for Concomitant Use with Moderate CYP3A4 Inhibitors Starting Dosage Maximum Dosage Hyperprolactinemia-associated dysfunction in adults 1.25 mg once daily (one-half of a tablet) 3.75 mg once daily Prolactin-secreting adenomas in adult and pediatric patients 11 years of age and older 1.25 mg once daily 2.5 mg once daily Acromegaly in adults 1.25 mg once daily 25 mg once daily Idiopathic or postencephalitic parkinsonism in adults 1.25 mg once daily 12.5 mg twice daily
Dosing: Altered kidney function
Patients with Renal Impairment: The effect of renal function on the pharmacokinetics of bromocriptine has not been evaluated. Because parent drug and metabolites are almost completely excreted via metabolism, and only 6% eliminated via the kidney, renal impairment may not have a significant impact on the PK of bromocriptine and its metabolites.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness of bromocriptine mesylate have been established for the treatment of prolactin-secreting pituitary adenomas in pediatric patients 11 years of age and older. Use of bromocriptine mesylate for this indication is supported by evidence from adequate and well-controlled trials of bromocriptine mesylate in adults with hyerprolactinemia-associated dysfunction, with additional data in 14 bromocriptine mesylate-treated pediatric patients 11 to 15 years of age with prolactin-secreting pituitary macro-and microadenomas.
Chronic hypopituitarism complicated macroadenoma treatment in 5 of the responders, in patients treated with bromocriptine mesylate alone and in those treated with bromocriptine mesylate in combination with surgical treatment and/or pituitary irradiation. The safety and effectiveness of bromocriptine mesylate have not been established for the treatment of prolactin-secreting adenomas in pediatric patients less than 11 years of age.
The safety and effectiveness of bromocriptine mesylate have not been established in pediatric patients for the treatment of hyperprolactiniemia-associated dysfunction, acromegaly, or idiopathic Parkinson’s disease or postencephalitic parkinsonism.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Clinical studies of bromocriptine mesylate did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.
Administration
2.2 Important Administration Instructions Take bromocriptine mesylate orally with food because a high percentage of patients vomited after they received bromocriptine mesylate under fasting conditions.
US FDA labelDosage forms
Philippines
- Tablet: 2.5 mg
Registered products in the Philippines
2 products registered with the Food and Drug Administration (FDA) Philippines list Bromocriptine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
BrocriptexBromocriptine (as mesilate) | 2.5 mg TabletAlu/PVC blister pack x 10 tablets (box of 10 tablets) | Rx | Par LaboratoriesIndia | MedEthix, Inc. | DRP-15141 | May 15, 2027 | |
ParlodelBromocriptine (as mesylate) | 2.5 mg TabletBlister Pack x 10's (Box of 30's) | Rx | Novartis Farma S.P.A.Italy | Sandoz Philippines Corporation | DR-XY7404 | Jan 2, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS & STRENGTHS Tablets: 2.5 mg of bromocriptine, off-white, round, flat-faced, beveled-edge tablets, debossed “E” above the score and “280” below the score on one side and debossed “2.5” on the other side. Capsules: 5 mg of bromocriptine, hard gelatin capsule size 3 with caramel opaque cap imprinted “102” on the cap and white opaque body, imprinted with “PARLODEL” over “5 mg” on the body. Tablets:2.5 mg of bromocriptine (functionally scored) (3) Capsules: 5 mg of bromocriptine (3)
Warnings/Precautions
- Cardiac Valvulopathy and Pericardial Fibrosis: During bromocriptine mesylate treatment, monitor for the development of valvulopathy with a cardiac echocardiogram at intervals of 6 to 12 months or as clinically indicated and monitor for chest pain and signs and symptoms of heart failure (if heart failure occurs, exclude valvular fibrosis and pericarditis). Consider additional clinical and diagnostic monitoring at baseline and as necessary during bromocriptine mesylate treatment. Use bromocriptine mesylate in patients treated with other drugs associated with valvulopathy is not recommended. Discontinue bromocriptine mesylate if the patient has a new diagnosis of valvular regurgitation, valvular restriction, valve leaflet thickening, or pericarditis. (5.1)
- Pleural, Pulmonary and Retroperitoneal Fibrosis: During bromocriptine mesylate treatment monitor for signs and symptoms of progressive fibrosis, (e.g., pleuro-pulmonary disease, renal impairment, ureteral/abdominal vascular obstruction). Consider clinical and diagnostic monitoring for pleural, pulmonary, and retroperitoneal fibrosis at baseline and as necessary during bromocriptine mesylate treatment. If pleural, pericardial, retroperitoneal, or pulmonary fibrosis occur, discontinue bromocriptine mesylate (5.2)
- Hypotension/Orthostatic Hypotension: Check blood pressure at baseline and during treatment with bromocriptine mesylate …
5.1 Cardiac Valvulopathy and Pericardial Fibrosis
5.1 Cardiac Valvulopathy and Pericardial Fibrosis Before initiating bromocriptine mesylate, perform a cardiovascular evaluation, including with an echocardiogram, to evaluate for valvular disease. Bromocriptine mesylate is contraindicated in the presence of valvular disease or pericardial fibrosis. Bromocriptine mesylate is not recommended in patients treated with other drugs associated with valvulopathy.
Following bromocriptine mesylate treatment initiation, monitor for the development of valvulopathy with a cardiac echocardiogram at intervals of 6 to 12 months or as clinically indicated with new onset edema, cardiac murmur, dyspnea, or heart failure. During bromocriptine mesylate treatment, monitor for chest pain and signs and symptoms of heart failure and if heart failure occurs, valvular fibrosis and pericarditis should be excluded.
Consider clinical and diagnostic monitoring such as erythrocyte sedimentation rate, serum creatinine measurements, chest-x-ray, and other investigations and cardiac imaging at baseline and as necessary while patients are treated with during bromocriptine mesylate treatment. Discontinue bromocriptine mesylate if the patient has a new diagnosis of valvular regurgitation, valvular restriction, valve leaflet thickening, or pericarditis.
Cases of cardiac valvulopathy have occurred in bromocriptine mesylate-treated patients. Pericardial effusions, as well as constrictive pericarditis, have been reported in bromocriptine mesylate-treated patients, particularly those on long-term and high-dosage treatment.
5.2 Pleural, Pulmonary, and Retroperitoneal Fibrosis
5.2 Pleural, Pulmonary, and Retroperitoneal Fibrosis Bromocriptine mesylate is contraindicated in patients with a history of pleural, pulmonary, or retroperitoneal fibrosis. During Bromocriptine mesylate treatment monitor for signs and symptoms of progressive fibrosis, including: Pleuro-pulmonary disease (e.g., dyspnea, shortness of breath, persistent cough, chest pain).
Renal impairment or ureteral/abdominal vascular obstruction (e.g., pain in the loin/flank, lower limb edema, abdominal masses or tenderness that may indicate retroperitoneal fibrosis). Consider clinical and diagnostic monitoring for pleural, pulmonary, and retroperitoneal fibrosis such as with erythrocyte sedimentation rate, serum creatinine measurements, chest-x-ray, and other investigations at baseline and as necessary during bromocriptine mesylate treatment.
If pleural, pericardial, retroperitoneal, or pulmonary fibrosis occur, discontinue bromocriptine mesylate. Pleural and Pulmonary Fibrosis Patients with unexplained pleuropulmonary disorders should be examined thoroughly and discontinuation of bromocriptine mesylate therapy should be considered. Pleural effusions, pleural fibrosis, and pulmonary fibrosis have been reported in bromocriptine mesylate-treated patients, particularly those on long-term and high-dosage treatment.
In those instances in which bromocriptine mesylate treatment was stopped, the changes slowly reverted towards normal. Retroperitoneal Fibrosis To ensure recognition of retroperitoneal fibrosis at an early reversible stage recommend that patients on long-term and high-dosage treatment should be monitored for its manifestations (e.g., back pain, lower limb edema, impaired kidney function).
Bromocriptine mesylate should be withdrawn if fibrotic changes in the retroperitoneum are diagnosed or suspected. Retroperitoneal fibrosis has been reported in a few bromocriptine mesylate-treated patients, particularly those on long-term and high-dosage treatment. Retroperitoneal fibrosis has been reported in a few patients with Parkinson’s disease who received long-term bromocriptine mesylate therapy (2 to 10 years) in dosages that ranged from 30 mg daily to 140 mg daily (9.3, 1.4, and 1.4 times the maximum recommended bromocriptine mesylate dosage for the hyperprolactionemia-associate dysfunction, acromegaly, and idiopathic Parkinson’s disease or postencephalitic parkinsonism indications, respectively [see Dosage and Administration (2.6)]).
5.3 Hypotension/Orthostatic Hypotension
5.3 Hypotension/Orthostatic Hypotension Hypotension/Orthostatic Hypotension Check blood pressure at baseline and during treatment with bromocriptine mesylate and monitor for hypotension. Instruct patients to report dizziness or lightheadedness with changes in position to their healthcare provider. Particular care should be exercised in bromocriptine mesylate-treated patients when driving a vehicle or operating hazardous machinery.
Hypotensive reactions may occur during bromocriptine mesylate treatment, especially during the first days of treatment. Orthostatic Hypotension in Patients with Parkinson’s Disease Patients with Parkinson’s disease being treated with dopaminergic agonists, including bromocriptine mesylate, should be monitored for signs and symptoms of orthostatic hypotension, especially during dose escalation, and should be informed of this risk because patients with Parkinson’s disease may have an impaired capacity to respond to an orthostatic challenge.
5.4 Risks with Use of Bromocriptine Mesylate for Postpartum Lactation Inhibition or…
5.4 Risks with Use of Bromocriptine Mesylate for Postpartum Lactation Inhibition or Suppression Avoid use of bromocriptine mesylate for the inhibition or suppression of postpartum physiologic lactation. Use of bromocriptine mesylate for this unapproved use has been associated with serious adverse reactions, including hypertension, psychotic reactions, acute myocardial infarction, seizures (including status epilepticus), stroke, and death.
Hypertension has occurred at the initiation of bromocriptine mesylate therapy, but often in the second week of therapy. Seizures have been reported with and without the prior development of hypertension. Stroke has mostly occurred in postpartum females whose prenatal and obstetric courses had been uncomplicated. Many of the bromocriptine mesylate-treated patients who experienced seizures (including cases of status epilepticus) and/or strokes reported developing a constant and often progressively severe headache accompanied by visual disturbance hours to days prior to the acute event.
Some cases of strokes and seizures were also preceded by visual disturbances (blurred vision, and transient cortical blindness). In postmarketing experience in the U.S., serious adverse reactions reported in bromocriptine mesylate-treated postpartum patients included 72 cases of seizures (including 4 cases of status epilepticus), 30 cases of stroke, and 9 cases of myocardial infarction.
One stroke case was associated with sagittal sinus thrombosis, and another was associated with cerebral and cerebellar vasculitis. One case of myocardial infarction was associated with unexplained disseminated intravascular coagulation and a second occurred in conjunction with use of another ergot alkaloid.
5.5 Impulse Control Disorders and Compulsive Behaviors
5.5 Impulse Control Disorders and Compulsive Behaviors Because patients may not recognize impulse control and compulsive behaviors as abnormal, it is important for healthcare providers to specifically ask patients or their caregivers about the development of new or increased gambling urges, sexual urges, uncontrolled spending, binge or compulsive eating, or other urges while being treated with bromocriptine mesylate. Consider dosage reduction or stopping bromocriptine mesylate if a patient develops such urges while taking bromocriptine mesylate.
Patients can experience intense urges to gamble or to spend money, increased sexual urges, binge eating, and/or other intense urges, and the inability to control these urges while taking one or more drugs that increase central dopaminergic tone, including bromocriptine mesylate. In some cases, these urges were reported to have stopped when the dosage was reduced, or the drug was discontinued.
5.6 Falling Asleep During Activities of Daily Living
5.6 Falling Asleep During Activities of Daily Living Before initiating treatment with bromocriptine mesylate, advise patients of the potential to develop drowsiness and specifically ask them about factors that may increase their risk for somnolence with dopaminergic drugs, such as concomitant sedating drugs or the presence of a sleep disorder. If a patient develops daytime sleepiness or episodes of falling asleep during activities that require full attention (e.g., driving a motor vehicle, conversations, eating), consider reducing the bromocriptine mesylate dosage or discontinuing bromocriptine mesylate.
If a decision is made to continue bromocriptine mesylate, advise the patient to avoid driving or performing potentially dangerous activities. Patients treated with dopaminergic drugs, including bromocriptine mesylate, have reported falling asleep while engaged in activities of daily living, including the operation of motor vehicles, which sometimes has resulted in accidents.
Patients may not perceive warning signs, such as excessive drowsiness, or they may report feeling alert immediately prior to the event.
5.7 Visual Impairment in Patients with Prolactin-secreting Adenomas
5.7 Visual Impairment in Patients with Prolactin-secreting Adenomas Recommend monitoring of visual fields in bromocriptine mesylate-treated patients with macroprolactinoma for an early recognition of secondary field loss due to chiasmal herniation. Bromocriptine mesylate-patients with rapidly progressive visual field loss should be evaluated by a neurosurgeon to help decide on the most appropriate therapy.
In some bromocriptine mesylate-patients patients, a secondary deterioration of visual fields may develop (despite normalized prolactin levels and tumor shrinkage) which may result from traction on the optic chiasm which is pulled down into the now partially empty sella. Reduction of the bromocriptine mesylate dosage may improve the visual field defect (there may be some elevation of prolactin and tumor re-expansion).
The relative efficacy of bromocriptine mesylate versus surgery in preserving visual fields in patients with prolactin-secreting adenomas is not known.
5.8 Exacerbation of Psychosis in Patients with Severe
5.8 Exacerbation of Psychosis in Patients with Severe Psychotic Disorders The use of bromocriptine mesylate in patients with severe psychotic disorders is not recommended. In patients with severe psychotic disorders, treatment with a dopamine receptor agonist including bromocriptine mesylate may exacerbate the psychosis or may diminish the effectiveness of drugs used to treat the severe psychotic disorder.
5.9 Risks in Patients with Hereditary Problems of Galactose Intolerance, Severe Lactase…
5.9 Risks in Patients with Hereditary Problems of Galactose Intolerance, Severe Lactase Deficiency, or Glucose-Galactose Malabsorption Avoid use of bromocriptine mesylate in patients with rare hereditary problems of galactose intolerance, severe lactase deficiency, or glucose-galactose malabsorption. Bromocriptine mesylate tablets and capsules contains lactose as an inactive ingredient.
The use of lactose in patients with rare hereditary problems of galactose intolerance, severe lactase deficiency, or glucose-galactose malabsorption increases the risk of diarrhea, abdominal pain, bloating, and malabsorption.
5.10 Additional Clinically Significant Adverse Reactions and Risks in Patients with Acromegaly…
5.10 Additional Clinically Significant Adverse Reactions and Risks in Patients with Acromegaly Cold-sensitive Digital Vasospasm Vasospam may be prevented in bromocriptine mesylate-treated patients by keeping the fingers warm. Cold-sensitive digital vasospasm has been observed in some bromocriptine mesylate-treated patients with acromegly.
If vasospasm occurs, it can be reversed by reducing the bromocriptine mesylate dosage. Gastrointestinal Bleeding Patients with a history of peptic ulcer or gastrointestinal bleeding should be monitored carefully during bromocriptine mesylate treatment. Cases of severe gastrointestinal bleeding from peptic ulcers have been reported, some fatal, in bromocriptine mesylate-treated patients.
Tumor Expansion Because the natural history of growth hormone-secreting tumors is unknown, bromocriptine mesylate-treated patients with acromegaly should be carefully monitored and, if evidence of tumor expansion develops, discontinuation of bromocriptine mesylate treatment and alternative procedures should be considered. Possible growth hormone-secreting tumor expansion has been reported in a few bromocriptine mesylate-treated patients.
Withdrawal Adverse Reactions After Rapid Dosage Reduction or Discontinuation Prior to bromocriptine mesylate discontinuation, patients with acromegaly should be informed about a potential withdrawal symptom, and closely monitored during and after bromocriptine mesylate discontinuation. Bromocriptine mesylate discontinuation should be undertaken gradually whenever possible.
In case of severe withdrawal symptoms, consider re-administration of bromocriptine mesylate in patients with acromegaly at the lowest effective dosage.
5.11 Additional Clinically Significant Adverse Reactions and Risks in Patients with Idiopathic…
5.11 Additional Clinically Significant Adverse Reactions and Risks in Patients with Idiopathic Parkinson’s Disease or Postencephalitic Parkinsonism Mental Disturbances and Psychotic Symptoms Bromocriptine mesylate administered alone or concomitantly with levodopa may cause hallucinations (visual or auditory). Hallucinations may be accompanied by abnormal thinking and behavior which may present with one or more symptoms, including paranoid ideation, delusions, confusion, psychotic-like behavior, disorientation, aggressive behavior, agitation, and delirium.
Symptoms may be more frequent at higher dosages. Because of the risk of exacerbation of mental disturbances in patients with Parkison’s disease-related dementia, consider a lower bromocriptine mesylate dosage in these patients. The use of bromocriptine mesylate in patients with severe psychotic disorders is not recommended [see Warnings and Precautions (5.8)].
Hallucinations usually resolve with bromocriptine mesylate dosage reduction; occasionally, discontinuation of bromocriptine mesylate is required. Rarely, after high bromocriptine mesylate dosage treatment, hallucinations have persisted for several weeks following bromocriptine mesylate discontinuation. Risk of Exacerbation of Arrhythmias in Patients with a History of Myocardial Infarction with a Residual Arrthythmia Caution should be exercised when administering bromocriptine mesylate to patients with a history of myocardial infarction who have a residual atrial, nodal, or ventricular arrhythmia.
Withdrawal Adverse Reactions After Rapid Dosage Reduction or Discontinuation Prior to bromocriptine mesylate discontinuation, patients should be informed about potential withdrawal symptoms, and closely monitored during and after bromocriptine mesylate discontinuation. Bromocriptine mesylate discontinuation should be undertaken gradually whenever possible, even if the patient is to remain on levodopa.
In case of severe withdrawal symptoms, consider re-administration of bromocriptine mesylate at the lowest effective dosage. A symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dosage reduction or withdrawal of antiparkinsonian therapy.
Symptoms including apathy, anxiety, depression, fatigue, insomnia, sweating, and pain have been reported during taper or after discontinuation of dopamine agonists, including bromocriptine mesylate. These withdrawal symptoms generally have not responded to levodopa.
Drug interactions
Drug interactions (US label) US FDA label
7 DRUG INTERACTIONS Alcohol Alcohol may potentiate bromocriptine mesylate-associated adverse reactions. Dopamine Antagonists The concomitant use of bromocriptine mesylate with dopamine antagonists resulted in a decreased efficacy of bromocriptine mesylate. Strong and Moderate CYP3A4 Inhibitors Avoid concomitant use of bromocriptine mesylate with strong CYP3A4 inhibitors.
Follow the recommended bromocriptine mesylate dosage modifications during concomitant use with moderate CYP3A4 inhibitors [see Dosage and Administration (2.7)]. Bromocriptine is a substrate of CYP3A4 [see Clinical Pharmacology (12.3)]. Concomitant use with strong and moderate CYP3A4 inhibitors increases bromocriptine exposure [see Clinical Pharmacology (12.3)], which may increase the risk of bromocriptine mesylate-associated adverse reactions.
Ergot Alkaloids Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended. If use is unavoidable, dosage reduction may be necessary in those cases where high dosages of bromocriptine mesylate are being used (such as patients with Parkinson’s disease). Alcohol: Alcohol may potentiate bromocriptine mesylate adverse reactions (7).
Dopamine Antagonists: Concomitant use of bromocriptine mesylate with dopamine antagonists: decreased efficacy of bromocriptine mesylate (7). Strong and Moderate CYP3A4 Inhibitors: Avoid concomitant use of bromocriptine mesylate with strong CYP3A4 inhibitors. Dosage modifications are recommended for bromocriptine mesylate when used with a concomitant moderate CYP3A4 inhibitor (7).
Ergot Alkaloids: Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended. If use is unavoidable, dosage reduction may be needed where high bromocriptine mesylate dosages are used (7).
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
In vitro studies using human liver microsomes showed that bromocriptine has a high affinity for CYP3A and hydroxylations at the proline ring of the cyclopeptide moiety constituted a main metabolic pathway.
Drug Interaction Studies Inhibitors and/or potent substrates for CYP3A4 might inhibit the clearance of bromocriptine and lead to increased bromocriptine levels [see Drug Interactions (7)].
Bromocriptine is a CYP3A4 inhibitor with a calculated IC50 value of 1.69 μM.6 Given the low therapeutic bromocriptine concentrations in patients (Cmax=0.82 nM), a significant alteration of the metabolism of a second drug whose clearance is mediated by CYP3A4 is not be expected.
The concomitant use of erythromycin, a moderate CYP3A4 inhibitor, with bromocriptine mesylate was shown to increase the plasma levels of bromocriptine (mean AUC and Cmax values increased 3.7 fold and 4.6-fold, respectively) [see Dosage and Administration (2.6) and Drug Interactions (7)].
Strong and Moderate CYP3A4 Inhibitors Avoid concomitant use of bromocriptine mesylate with strong CYP3A4 inhibitors.
Follow the recommended bromocriptine mesylate dosage modifications during concomitant use with moderate CYP3A4 inhibitors [see Dosage and Administration (2.7)].
Bromocriptine is a substrate of CYP3A4 [see Clinical Pharmacology (12.3)] .
Concomitant use with strong and moderate CYP3A4 inhibitors increases bromocriptine exposure [see Clinical Pharmacology (12.3)], which may increase the risk of bromocriptine mesylate-associated adverse reactions.
Adverse reactions
- The following clinically significant adverse reactions are described elsewhere in the labeling: Cardiac Valvulopathy and Pericardial Fibrosis [see Warnings and Precautions (5.1)] Pleural, Pulmonary, and Retroperitoneal Fibrosis [see Warnings and Precautions (5.2)] Hypotension/Orthostatic Hypotension [see Warnings and Precautions (5.3)] Risks with Use of Bromocriptine Mesylate for Postpartum Lactation Inhibition or Suppression [see Warnings and Precautions (5.4)] Impulse Control Disorders and Compulsive Behaviors [see Warnings and Precautions (5.5)] Falling Asleep During Activities of Daily Living [see Warnings and Precautions (5.6)] Visual Impairment in Patients with Prolactin-secreting Adenomas [see Warnings and Precautions (5.7)] Exacerbation of Psychosis in Patients with Severe Psychotic Disorders [see Warnings and Precautions (5.8)] Risks in Patients with Hereditary Problems of Galactose Intolerance, Severe Lactase Deficiency, or Glucose-Galactose Malabsorption [see Warnings and Precautions (5.9)] Additional Clinically Significant Adverse Reactions and Risks in Patients with Acromegaly [see Warnings and Precautions (5.10)] Additional Clinically Significant Adverse Reactions and Risks in Patients with Idiopathic Parkinson’s Disease or Postencephalitic Parkinsonism [see Warnings and Precautions (5.11)] Most common adverse reactions: (6.1)
- Hyperprolactinemia-Associated …
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse Reactions in Studies of Patients with Hyperprolactinemia-Associated Dysfunctions and Prolactin-secreting Adenomas Bromocriptine mesylate therapy was discontinued in approximately 5% of patients with hyperprolactinemia-associated dysfunctions.
The most common adverse reactions in bromocriptine mesylate-treated patients with hyperprolactinemia-associated dysfunctions were nausea (49%), headache (19%), dizziness (17%), fatigue (7%), lightheadedness (5%), vomiting (5%), abdominal cramps (4%), nasal congestion (3%), constipation (3%), diarrhea (3%) and drowsiness (3%). A few cases of cerebrospinal fluid rhinorrhea have been reported in bromocriptine mesylate-treated patients with large prolactinomas who have received previous transsphenoidal surgery, pituitary radiation, or both.
Adverse Reactions in Studies of Patients with Acromegaly The most frequent adverse reactions in bromocriptine mesylate-treated patients with acromegaly were nausea (18%), constipation (14%), postural/orthostatic hypotension (6%), anorexia (4%), dry mouth/nasal stuffiness (4%), indigestion/dyspepsia (4%), digital vasospasm (3%), drowsiness/tiredness (3%) and vomiting (2%). Adverse reactions that occurred in less than 2% of bromocriptine mesylate-treated patients with acromegaly were gastrointestinal bleeding, dizziness, exacerbation of Raynaud’s syndrome, headache, and syncope.
Adverse reactions that occured in less than 1% of bromocriptine mesylate-treated patients with acromegaly were hair loss, alcohol potentiation, faintness, lightheadedness, arrhythmia, ventricular tachycardia, decreased sleep requirement, visual hallucinations, lassitude, shortness of breath, bradycardia, vertigo, paresthesia, sluggishness, vasovagal attack, delusional psychosis, paranoia, insomnia, heavy headedness, reduced tolerance to cold, tingling of ears, facial pallor, and muscle cramps. Adverse Reactions in Studies of Patients with Idiopathic Parkinson’s Disease or Postencephalitic Parkinsonism In clinical trials in bromocriptine mesylate-treated patients with idiopathic Parkinson’s disease or postencephalitic parkinsonism where patients had a reduction in the levodopa/carbidopa dosage, the most common adverse reactions were nausea, abnormal involuntary movements, hallucinations, confusion, “on-off’’ phenomenon, dizziness, drowsiness, faintness/fainting, vomiting, asthenia, abdominal discomfort, visual disturbance, ataxia, insomnia, depression, hypotension, shortness of breath, constipation, and vertigo.
Less common adverse reactions in bromocriptine mesylate-treated patients with idiopathic Parkinson’s disease or postencephalitic parkinsonismwere anorexia, anxiety, blepharospasm, dry mouth, dysphagia, edema of the feet and ankles, erythromelalgia, epileptiform seizure, fatigue, headache, lethargy, mottling of skin, nasal stuffiness, nervousness, nightmares, paresthesia, skin rash, urinary frequency, urinary incontinence, urinary retention, and rarely, signs and symptoms of ergotism such as tingling of fingers, cold feet, numbness, muscle cramps of feet and legs or exacerbation of Raynaud’s syndrome. Abnormalities in laboratory tests in bromocriptine mesylate-treated patients with idiopathic or postencephalitic Parkinson’s disease may include elevations in blood urea nitrogen, ALT, AST, GGPT, CPK, alkaline phosphatase and uric acid, which are usually transient.
Additional Adverse Reactions in Clinical Studies of Bromocriptine Mesylate During clinical trials, dizziness, drowsiness, faintness, fainting, and syncope have been reported early in the course of bromocriptine mesylate therapy.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of bromocriptine mesylate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Cardiac disorders: Pericardial effusion, constrictive pericarditis, tachycardia, bradycardia,arrhythmia, cardiac valve fibrosis. Ear and labyrinth disorders: Tinnitus. Eye disorders: Visual disturbance, vision blurred. General disorders and administration site conditions: Fatigue, peripheral edema. Gastrointestinal disorders: Nausea, constipation, vomiting, dry mouth, diarrhea, abdominalpain, retroperitoneal fibrosis, gastrointestinal ulcer, gastrointestinal hemorrhage.
Musculoskeletal and connective tissue disorders: Leg cramps. Nervous system disorders: Headache, drowsiness, dizziness, dyskinesia, somnolence,paraesthesia, excess daytime somnolence, sudden onset of sleep. Respiratory, thoracic and mediastinal disorders: Nasal congestion, pleural effusion, pleuralfibrosis, pleurisy, pulmonary fibrosis, dyspnea.
Psychiatric disorders: Confusion, psychomotor agitation/excitation, hallucinations, psychoticdisorders, insomnia, libido increase, hypersexuality, and impulse control/compulsive behaviors(including gambling, spending, and other intense urges). Skin and subcutaneous tissue disorders: Allergic skin reactions, hair loss. Vascular disorders: Hypotension, orthostatic hypotension (very rarely leading to syncope),reversible pallor of fingers and toes induced by cold (especially in patients with history of Raynaud's phenomenon).
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Pregnancy in Patients with Hyperprolactinemia-Associated Dysfunction and Prolactin-Secreting Adenomas: In patients being treated with bromocriptine mesylate for hyperprolactinemia, bromocriptine mesylate should generally be withdrawn when pregnancy is diagnosed. If bromocriptine mesylate is continued or reinstituted in select patients to manage a prolactin-secreting macroadenoma and a patient experiences a hypertensive disorder of pregnancy, the benefit of continuing bromocriptine mesylate should be weighed against the possible risk of its use during a hypertensive disorder of pregnancy.
Pregnancy in Patients with Acromegaly: In patients being treated with bromocriptine mesylate for acromegaly who subsequently become pregnant, a decision should be made as to whether bromocriptine mesylate continues to be medically necessary or can be withdrawn. Bromocriptine mesylate should be withdrawn in those who experience hypertensive disorders of pregnancy (including eclampsia, preeclampsia, or pregnancy-induced hypertension) unless bromocriptine mesylate use is necessary.
Idiopathic Parkinson’s Disease or Postencephalitic Parkinsonism: In patients being treated with bromocriptine mesylate for idiopathic Parkinson’s disease or postencephalitic parkinsonism, there are no adequate data on the developmental risk associated with the use of the bromocriptine mesylate in pregnant women. If the decision is made to discontinue bromocriptine mesylate, adverse reactions associated with rapid dosage reduction or withdrawal should be considered [see Warnings and Precatutions (5.11)].
Risk of Major Birth Defects and Miscarriage: The estimated background risk of major birth defects and miscarriage in patients with hyperprolactinemia-associated dysfunctions, prolactin-secreting ademonas, acromegaly, or idiopathic Parkinson’s disease or postencephalitic parkinsonism is unknown. All pregnancies have a risk of birth defect, loss, or other adverse outcomes.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. The incidence of birth defects in 1,109 live births was 3.3% in neonates/infants born to mothers who received bromocriptine mesylate during pregnancy (see Data).
Clinical Considerations Maternal Adverse Reactions: Bromocriptine mesylate-treated patients should be monitored closely throughout pregnancy for signs and symptoms that may signal the enlargement of a previously undetected or existing prolactin-secreting tumor. Discontinuation of bromocriptine mesylate treatment in patients with known macroadenomas has been associated with rapid regrowth of tumor and increase in serum prolactin in most cases.
Prolactin-secreting adenomas may expand and compression of the optic or other cranial nerves may occur, emergency pituitary surgery becoming necessary. In most cases, the compression resolves following delivery. Reinitiation of bromocriptine mesylate treatment has been reported to produce improvement in the visual fields of patients in whom nerve compression has occurred during pregnancy.
Postpartum Period: Avoid use of bromocriptine mesylate for the inhibition or suppression of postpartum physiologic lactation because of the risk of serious adverse reactions [see Warnings and Precautions (5.4)]. Bromocriptine mesylate should not be used during the postpartum period in women with a history of coronary artery disease and other severe cardiovascular conditions unless bromocriptine mesylate use is necessary.
Symptomatic hypotension can occur in bromocriptine mesylate-treated patients. In postpartum studies, decreases in supine systolic blood pressure (SBP) and diastolic blood pressure of greater than 20 mm and 10 mm Hg, respectively, were observed in almost 30% of bromocriptine mesylate-treated patients. On occasion, the drop in supine SBP was as much as 50-59 mm of Hg.
Data Human Data: The following information is based on 1,276 pregnancies in bromocriptine mesylate-treated females. In the majority of cases, bromocriptine mesylate was discontinued within 8 weeks into pregnancy (mean 29 days), however, eight patients received the bromocriptine mesylate continuously throughout pregnancy.
The mean bromocriptine mesylate dosage for pregnant patients was 6 mg (range 1-40 mg) per day. Of these 1,276 pregnancies, there were 1,088 full-term deliveries (4 stillborn), 145 spontaneous abortions (11%), and 28 induced abortions (2%). Moreover, 12 extrauterinegravidities and 3 hydatidiform moles (twice in the same patient) caused early termination of pregnancy.
These data compare favorably with the abortion rate (11% -25%) cited for pregnancies induced by clomiphene citrate, menopausal gonadotropin, and chorionic gonadotropin. There is no evidence that bromocriptine mesylate contributed to the type or incidence of birth defects in these infants. Animal Data: Administration of 10-30 mg/kg of bromocriptine to rats (two strains) on days 6 to 15 postcoitum as well as a single bromocriptine dose of 10 mg/kg on day 5 postcoitum interfered with implantation.
Administration of 3 mg/kg of bromocriptine on days 6 to 15 were without effect on nidation, and did not produce any anomalies in the rats. Rats treated with 30 mg/kg of bromocriptine from day 8-15 postcoitum (i.e., after implantation) produced increased prenatal mortality with increased incidence of embryonic resorption.
One anomaly, aplasia of spinal vertebrae and ribs, was found in the group of 262 fetuses derived from the dams. No fetotoxic effects were found in offspring of dams treated with bromocriptine during the peri-or postnatal period. Two studies were conducted in rabbits (two strains) to determine the potential of bromocriptine to interfere with nidation.
Bromocriptine dose levels of 100 or 300 mg/kg/day from day 1 to day 6 postcoitum did not adversely affect nidation. The high dose was approximately 63 times the maximum human recommended dose administered in controlled clinical trials in patients with acromegaly (100 mg/day), based on body surface area. In New Zealand white rabbits, some embryo mortality occurred at a bromocriptine dose of 300 mg/kg which was a reflection of overt maternal toxicity.
Three studies were conducted in two strains of rabbits to determine the teratological potential of bromocriptine at dose levels of 3, 10, 30, 100, and 300 mg/kg administered from day 6 to day 18 postcoitum. In two studies with the Yellow-silver strain, cleft palate was found in 3 and 2 fetuses at maternally toxic bromocriptine doses of 100 and 300 mg/kg, respectively.
One control fetus also exhibited this anomaly. In the third study conducted with New Zealand white rabbits using an identical protocol, no cleft palates were observed. No teratological or embryotoxic effects of bromocriptine were produced in any of six offspring from six monkeys at a bromocriptine dose level of 2 mg/kg.
Mechanism of action
12.1 Mechanism of Action Bromocriptine mesylate contains bromocriptine, an ergot derivative and dopamine receptor agonist, which activates post-synaptic dopamine receptors. Dopaminergic neurons in the tuberoinfundibular process release dopamine that modulates the secretion of prolactin from the anterior pituitary; in the corpus striatum the dopaminergic neurons are involved in the control of motor function.
Bromocriptine induces stereotyped behavior in rodents and turning behavior in rats (e.g., rats move in circles) that have unilateral lesions in the substantia nigra. These actions, characteristic of those produced by dopamine, are inhibited by dopamine antagonists and suggest a direct action of bromocriptine on striatal dopamine receptors.
Bromocriptine inhibits the secretion of prolactin in humans, with little or no effect on other pituitary hormones, except in patients with acromegaly, where bromocriptine lowers elevated blood levels of growth hormone in the majority of patients. Bromocriptine produces its therapeutic effect in the treatment of idiopathic Parkinson’s disease or postencephalitic parkinsonism, a clinical condition characterized by a progressive deficiency in dopamine synthesis in the substantia nigra, by directly stimulating the dopamine receptors in the corpus striatum.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Clinically, bromocriptine mesylate significantly reduces plasma levels of prolactin in patients with hyperprolactinemia. The inhibition of physiological lactation as well as galactorrhea in pathological hyperprolactinemic states is obtained at dose levels that do not affect secretion of other tropic hormones from the anterior pituitary. Cardiac Electrophysiology There is insufficient information to characterize the effect of bromocriptine mesylate on the QTc interval.
Pharmacokinetics
12.3 Pharmacokinetics Following single 5 mg bromocriptine mesylate dose (two 2.5 mg tablets) to five healthy volunteers under fasted conditions, the mean peak bromocriptine plasma levels, time to reach peak bromocriptine plasma concentrations and elimination half-life were 465 pg/mL ± 226, 2.5 hours ± 2 and 4.9 hours, respectively.
Excretion: About 82% and 6% of the radioactive bromocriptine dose orally administered was recovered in feces and urine, respectively.
Because parent drug and metabolites are almost completely excreted via metabolism, and only 6% eliminated via the kidney, renal impairment may not have a significant impact on the PK of bromocriptine and its metabolites.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Following single 5 mg bromocriptine mesylate dose (two 2.5 mg tablets) to five healthy volunteers under fasted conditions, the mean peak bromocriptine plasma levels, time to reach peak bromocriptine plasma concentrations and elimination half-life were 465 pg/mL ± 226, 2.5 hours ± 2 and 4.9 hours, respectively. Linear relationship was found between single doses of bromocriptine mesylate and Cmax and AUC in the dose range of 1 to 7.5 mg.
The pharmacokinetics of bromocriptine metabolites is unknown. Following administration of 5 mg of bromocriptine mesylate twice daily for 14 days, the bromocriptine Cmax and AUC at steady-state were 628 ± 375 pg/mL and 2377 ± 1186 pg*hr/mL, respectively. Absorption Effect of Food: Food did not significantly affect the systemic bromocriptine exposure following administration of 2.5 mg of bromocriptine mesylate.
Distribution In vitro experiments showed that bromocriptine was 90% -96% bound to serum albumin. Elimination Metabolism: Bromocriptine undergoes extensive first-pass biotransformation, reflected by complex metabolite profiles and by almost complete absence of parent drug in urine and feces. In vitro studies using human liver microsomes showed that bromocriptine has a high affinity for CYP3A and hydroxylations at the proline ring of the cyclopeptide moiety constituted a main metabolic pathway.
The participation of other major CYP enzymes such as 2D6, 2C8, and 2C19 in the metabolism of bromocriptine has not been evaluated. Excretion: About 82% and 6% of the radioactive bromocriptine dose orally administered was recovered in feces and urine, respectively. Bromolysergic acid and bromoisolysergic acid accounted for half of the radioactivity in urine.
Specific Populations The effect of age, race, and sex on the pharmacokinetics of bromocriptine and its metabolites has not been evaluated. Patients with Renal Impairment: The effect of renal function on the pharmacokinetics of bromocriptine has not been evaluated. Because parent drug and metabolites are almost completely excreted via metabolism, and only 6% eliminated via the kidney, renal impairment may not have a significant impact on the PK of bromocriptine and its metabolites.
Patients with Hepatic Impairment: The effect of hepatic impairment on the PK of bromocriptine and its metabolites has not been evaluated. Drug Interaction Studies Inhibitors and/or potent substrates for CYP3A4 might inhibit the clearance of bromocriptine and lead to increased bromocriptine levels [see Drug Interactions (7)].
Bromocriptine is a CYP3A4 inhibitor with a calculated IC50 value of 1.69 μM.6 Given the low therapeutic bromocriptine concentrations in patients (Cmax=0.82 nM), a significant alteration of the metabolism of a second drug whose clearance is mediated by CYP3A4 is not be expected. The potential effect of bromocriptine and its metabolites to act as CYP inducers has not been reported.
The concomitant use of erythromycin, a moderate CYP3A4 inhibitor, with bromocriptine mesylate was shown to increase the plasma levels of bromocriptine (mean AUC and Cmax values increased 3.7 fold and 4.6-fold, respectively) [see Dosage and Administration (2.6) and Drug Interactions (7)]. The concomitant use of bromocriptine mesylate and octreotide in patients with acromegaly led to increased plasma bromocriptine levels (bromocriptine AUC increased about 38%).
These changes in bromocriptione levels are not clinically significant.
Formulary and pricing (Philippines)
Formulary and coverage
| Philippine National Formulary | Listed as Bromocriptine (as mesilate) |
| PNF listing | Oral: 2.5 mg tabletRestrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Bromocriptine Mesylate · ANI Pharmaceuticals, Inc. [US FDA-approved label, version 4, July 27, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17f3a343-1782-4799-95ba-31dfe93be2cf
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .